Molecular mechanisms of tumor-bone interactions in osteolytic metastases

Critical Reviews in Eukaryotic Gene Expression

Volumn 10, Issue 2, 2000, Pages 159-178

  Chirgwin, John M ^a,b   Guise, Theresa A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bone metastasis; Breast cancer; Osteolysis; PTHrP; TGF

Indexed keywords

ANDROGEN; CYTOKINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NEUTRALIZING ANTIBODY; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; SEX HORMONE; STEROID HORMONE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

BONE METASTASIS; BREAST CANCER; HORMONAL REGULATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; METASTASIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0033757999     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/critreveukargeneexpr.v10.i2.50     Document Type: Review

References (138)

1. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium
2. Urokinase over-production results in increased skeletal metastasis by prostate cancer cells in vivo
3. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
4. Thymosin β15: A novel regulator of cell tumor motility upregulated in metastatic prostate cancer
5. Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein
6. Serum phosphohexose isomerase in cancer II: An index of tumor growth in metastatic carcinoma of the breast
7. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases
8. Scanning electron microscopy in bone pathology: Review of methods. Potential and applications
9. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer
10. Calcium stimulates parathyroid hormone-related protein production in Leydig tumor cells through a putative cationsensing mechanism
11. Parathyroid hormone related protein and hypercalcaemia in breast cancer
12. Parathyroid hormone related protein and skeletal morbidity in breast cancer
13. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy
14. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer
15. Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein
16. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
17. The clinical course of bone metastases from breast cancer
18. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts
19. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice
20. Proteinases in bone resorption: Obvious and less obvious roles
21. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo
22. RANK is essential for osteoclast and lymph node development
23. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma
24. Direct resorption of bone by human breast cancer cells in vitro
25. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells
26. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3
27. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
28. Regulation of PTHrP expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens
29. Markers of bone turnover for the management of patients with bone metastases from prostate cancer
30. Interleukin-18: Perspectives on the newest interleukin
31. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization
32. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy
33. Cancer and bone
34. Evidence for a causal role of parathyroid hormone-related protein in breast cancer-mediated osteolysis
35. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
36. Growth factors in bone matrix
37. Epidermal growth factor-stimulated parathyroid hormone-related protein expression involves increased gene transcription and mRNA stability
38. Nuclear targeting of secretory proteins
39. Production of PTHrP by primary breast cancers predicts improved patient survival and decreased bone metastases
40. TGFβ induces firbronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway
41. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
42. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro
43. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
44. Activated T lymphocytes support osteoclast formation in vitro
45. An experimental model of bone metastasis by human lung cancer cells: The role of parathyroid hormone-related protein in bone metastasis
46. Moonlighting proteins
47. Transforming growth factor β (TGFβ) stimulates tumor production of parathyroid hormone-related protein (PTHrP) via Smad-dependent and -independent mechanisms
48. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells
49. Parathyroid hormone-related protein of malignancy: Active synthetic fragments
50. Anticancer drug targets: Approaching angiogenesis
51. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors
52. Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): A paracrine regulator?
53. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
54. Unraveling the role of proteases in cancer
55. Mutational analysis of the ER gene in endometrial carcinoma
56. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
57. Phosphorylation at the cyclin-dependent kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear localization
58. A novel orthotopic model of breast cancer metastasis to bone
59. Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo
60. Autocrine motility factor (AMF) stimulates periosteal new bone formation
61. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma
62. An odyssey from breast to bone: Multi-step control of mammary metastases and osteolysis by matrix metalloproteinases
63. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling
64. Receptors for PTH and PTHrP: Their biological importance and functional properties
65. TGFβ signal transduction
66. Interleukins in the control of osteoclast differentiation
67. Induction of experimental bone metastasis in mice by transfection of integrin 4β1 into tumor cells
68. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model
69. Cadherin-6 mediates the heterotypic inter-actions between the hemopoietic osteoclast cell lineage and stromal cells in a murine model of osteoclast differentiation
70. Effects of transforming growth factor-β on parathyroid hormone-related protein production and ribonucleic acid expression by a squamous carcinoma cell line in vitro
71. Bone growth factors
72. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors
73. Parathyroid hormone-related protein purified from a human lung cancer cell line
74. Role of Ras and Mapks in TGFbeta signaling
75. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells
76. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts
77. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice
78. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells
79. Matrix metalloproteinases: Biologic activity and clinical implications
80. Cancer metastasis: Tumor cell and host organ properties important to metastasis to specific secondary sites
81. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption
82. TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis
83. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene
84. The distribution of secondary growths in cancer of the breast
85. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity
86. Modulation of transforming growth factor β activity in bone cultures by osteotropic hormones
87. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro
88. Tumour progression and angiogenesis in bone metastasis from breast cancer: New approaches to an old problem
89. Localization of parathyroid hormone-related protein in breast cancer metastasis: Increased incidence in bone compared with other sites
90. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
91. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo
92. Constitutively active PTH/PTHrP (PTHR) receptor signaling by breast cancer cells decreases bone metastases and TGFβ-stimulated PTHrP production
93. Control of osteoclast differentiation
94. Tumour invasion: Effects of cell adhesion and motility
95. Why do cancer cells metastasize into particular organs?
96. Extracellular calcium-sensing receptor (CaR) expression and its potential role in parathyroid hormone-related peptide (PTHrP) secretion in the H-500 rat Leydig cell model of humoral hypercalcemia of malignancy
97. The bisphosphonate residronate reduces metastatic human breast cancer burden in bone in nude mice
98. Increased interleukin-11 expression by breast cancer cells results in increased bone metastasis in mice
99. Interleukin-6 and interleukin-11 are differentially regulated in breast cancer cells
100. Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis
101. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
102. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer
103. Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein
104. Parathyroid hormone-like protein from human renal carcinoma cells structural and functional homology with parathyroid hormone
105. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
106. Hematopoiesis angiogenesis
107. Regulation of cell movement: The motogenic cytokines
108. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins
109. A parathyroid hormone-related protein implicated in malignant hypercalcemia: Cloning and expression
110. Heregulin regulation of autocrine motility factor expression in human tumor cells
111. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer
112. In vivo regulation of parathyroid hormone-related peptide messenger ribonucleic acid in the rat uterus by 17β-estradiol
113. Breast cancer cells interact with osteoblasts to support osteoclast formation
114. 3 integrin
115. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo
116. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone
117. Localization of parathyroid hormone-related protein mRNA expression and metastatic lesions by in situ hybridization
118. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
119. Human prostate-specific antigen: Structural and functional similarity with serine proteases
120. Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
121. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential
122. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region
123. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex
124. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
125. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
126. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
127. G protein-coupled extracellular Ca2+ (Ca2+o)-sensing receptor (CaR): Roles in cell signaling and control of diverse cellular functions
128. Convergence of TGFβ and vitamin D signaling pathways on SMAD transcriptional co-activators
129. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
130. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
131. TGF β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
132. The effects of transforming growth factor-β on breast cancer-mediated osteolysis are mediated by parathyroid hormone-related protein via the Smad signaling pathway
133. Expression of a constitutively active estrogen receptor (ER)-α increases parathyroid hormone-related protein (PTHrP) production and transforming growth factor (TGF)-β-responsiveness by human breast cancer cells
134. Inhibition of osteolytic metastasis of breast cancer by combined treatment with the bisphosphonate Ibandronate and tissue inhibitor of the matrix metalloproteinase-2
135. Cellular and molecular basis of preferential metastasis of breast cancer to bone
136. Transforming growth factor β increases stability of parathyroid hormone-related protein messenger RNA
137. An ER mutant with strong hormone-independent activity from a metastatic breast cancer
138. Regulation of Smad signalling by protein associations and signalling crosstalk